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SUPPLEMENTARY MATERIALS 
Cannabidiol reverses attentional bias to cigarette cues in a human 
experimental model of tobacco withdrawal.  
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Supplementary Method 
Participant recruitment 
 
Supplementary Figure 1: flow diagram for study recruitment and assessments. The final sample 
included 30 participants who completed all three sessions.  
Procedure  
Supplementary table 1: Schedule of assessments on the satiated and abstinent sessions.  
SATIATED ABSTINENT 
TIME   TIME    
0 Arrival 0 Arrival 
12 MPSS QSU [1] 5 MPSS QSU HR BP [1] 
30 Cigarette 10 Drug administration 
35 MPSS QSU [2] 70 MPSS QSU HR BP [2] 
60 Visual Probe  130 MPSS QSU HR BP [3] 
68 PRT 190 Visual Probe 
75 MPSS QSU [3] 198 PRT 
- - 200 MPSS QSU [4] 
Supplementary Results 
Time since last smoked 
There was a significant main effect of abstinence (F(1,29)= 3289.03, p<.001, η2p =.99) where on the 
satiated session, participants last smoked M: 0.41 (SD: 0.40) hours previously, in comparison to 
abstinent. There was no main effect of drug (F(1,29)=0.18, p=.675, η2p=.006). Participants last smoked 
M: 10.97 (SD:0.96) hours previously on the CBD session and M:11.03 (SD:0.95) on the PBO session.  
CO 
There was a significant main effect of abstinence (F(1,29)= 167.83 p<.001, η2p=.84) which shows CO 
was higher in the satiated condition (M: 17.73 ppm SD: 6.63) than in the abstinent conditions. There 
was no main effect of drug (F(1,29)=6.13, p=.019, η2p=.17) where CO was 4.27ppm (SD:2.23) for 
CBD and 4.17 (SD:2.69) for PBO. Thus abstinence was biologically verified.  
MPSS 
Amount of time spent with urge 
Pre-drug time spent with urges was significantly greater under abstinent than satiated sessions 
F(1,29)=27.96, p<.001, η2p=.49 suggesting abstinence increased the amount of time spent with urges 
to smoke. There was no different between CBD and PBO, pre-drug administration (p=0.536; JZS BF 
in support of the null= 5.86). To investigate if CBD attenuated craving in comparison to placebo on 
abstinent sessions, we conducted an ANOVA that showed a main effect of time (F(3,87)=8.65, p<.001, 
η2p=.23) which showed that time spent with urges decreased from T1 (3.17, 95% CI 2.79-3.64) to T3 
(2.40, 95% CI 1.97-2.82), and increased from T3 to T4 (2.80, 95% CI 2.38-3.22). However there was 
no effect of drug (p=1.00; JZS BF in support of the null= 7.08) There was no drug x time interaction 
F(2, 68)=.25, p=.81, η2p=0.00). 
Strength of urges 
Pre-drug strength of urges was significantly greater under abstinent than satiated sessions 
F(1,29)=26.26, p<.001, η2p=.48 suggesting abstinence increased the strength of urges. There was no 
different between CBD and PBO, pre drug administration (p=0.879; JZS BF in support of the null= 
6.99). To investigate if CBD attenuated craving in comparison to placebo on abstinent sessions, we 
conducted an ANOVA that showed a main effect of time (F(3,87)=4.33, p=.007, η2p=.13) which 
showed that time spent with urges decreased significantly from T1 (2.92, 95% CI 2.58-3.25) to T2 
(2.40, 95% CI 2.02-2.78), and increased from T2 to T3 (2.48, 95% CI 2.10-2.87) and T4 (2.73, 95% CI 
2.31-3.16). However there was no effect of drug (p=.61; JZS BF in support of the null= 6.20) There 
was no drug x time interaction F(3, 87)=0.65, p=0.58, η2p=0.02). 
Side effects 
Strong Drug effect: There was no main effect of drug (F(1,29)=.80, p=.379, η2p=.03) confirmed by 
Bayesian analysis (JZS BF:  4.82), time (F(2,58)=.37 p=.695, η2p =.01), or drug x time interaction 
(F(2,58)=2.18, p=.123,  η2p=.07).  
Good Drug effect: There was no main effect of drug (F(1,29)=.10, p=.922, η2p=.00) confirmed by 
Bayesian analysis (JZS BF:7.04), time (F(2,58)=2.76, p=.072,  η2p =.09), or drug x time interaction 
(F(2,58)=2.18, p=.123, η2p =.07). 
Willing to take drug again: There was no main effect of drug (F(1,29)=2.35, p=.136, η2p=.08) 
confirmed by Bayesian analysis (JZS BF: 2.35), time (F(2,58)=0.42, p=.661, η2p=.01, or drug x time 
interaction (F(2,58)=1.12, p=.306, η2p=.040). 
Like drug effect: There was no main effect of drug (F(1,29)=.01, p=.947, η2p=.00) confirmed by 
Bayesian analysis (JZS BF: 7.06) or drug x time interaction (F(2,58)=.03, p=.968, η2p=.00). There 
was a main effect of time (F(2,58)=3.53, p=.036, η2p=.11) which showed liking decreased over time. 
I have a stomach ache: There was no main effect of drug (F(1,29)=.00, p=.957,  η2p=.00) confirmed 
by Bayesian analysis (JZS BF:7.07), time (F(2,58)=.01, p=.988, ηp2=.000), or drug x time interaction 
(F(2,58)=1.44, p=.245, η2p=.05). 
I have a headache: There was a drug x time interaction (F(2,58)=3.17, p=.049,  η2p=.099). 
Exploration of the interaction showed no significant pairwise comparisons. There was no main effect 
of drug (F(1,29)=.04, p=.839, η2p=.00) confirmed by Bayesian analysis (JZS BF:6.93), or time 
(F(2,58)=.80, p=.456, η2p=.03).  
